blnk Healthcare Extend Portfolio of Respirators and Face Masks
With the end of the pandemic not in sight yet, TREKSTOR is announcing the expansion of its mask portfolio, therefore fulfilling the increased demand created by regulations and customers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005568/en/
blnk Type IIR disposable kids masks (Photo: Business Wire)
Some of the new entries are comprised of so-called filtering half-masks, commonly known as FFP2 and FFP3. The FFP2 masks with the model name BL-03N (item 30604) are packaged 2pcs per bag with the user manual directly printed on the outside. Comprised of 5 layers, the respirators have been type-approved by notified body SGS Fimko (0598) and are valid to use for 24 months from production. They are worn with ear-straps and come with a flexible nose guard included in the fabric.
Additionally, newly available are 20pcs boxes of two FFP3 masks with the model names LT-2020AP3 (item 30613) and LT-2020AP3V (item 30614), the later which includes a vent. Both masks are foldable, also include a nose-guard and are worn with elastic headbands, that can be adjusted to fit perfectly. Like all FFP3 masks, they filter ≥99% of particles, as has been confirmed by the notified body Applus (0370). This allows them to also be used in direct contact with COVID-19 positive patients.
„The demand for filtering half-masks has increased drastically over the last few weeks“, says Shimon Szmigiel, CEO of TREKSTOR. „Therefore, we decided to expand our portfolio beyond the already available KN95 respirators with CE approval based on EU guideline PPE-R 02.075.“
At the same time the face mask portfolio was updated. While the focus always has been on EN 14683:2019 certified masks of both types IIR and I, they were always only available for adults. But now TREKSTOR also offers type IIR face masks for children as well.
„Type IIR face masks filter ≥98% of exhaled air, therefore offering good protection for everyone around“, Simon Wiedemann, Head of Product Management explains. „With infections spreading in schools and day care centres more and more, wearing such masks consistently can help stop the spread of the virus dramatically.“
So kids can enjoy wearing a mask, TREKSTOR decided to offer them in 10 different designs, 5 each suited for boys and girls. Each design is packed 5pcs per re-sealable bag, if kids like to be surprised, the masks are also available in 5pcs mix packs with one mask of each design present within.
The kids masks are already in stock and can be ordered online at www.blnk-healthcare.com. The shop is also ready to accept pre-orders to FFP2 and FFP3 masks, which will then be fulfilled in early January. Interested parties can also declare their interest by sending an email to sales@blnk-healthcare.com. PR requests should be directed to pr@blnk-healthcare.com.
About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies and end-consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005568/en/
Contact information
Simon Wiedemann
Head of Marketing and Product
pr@blnk-healthcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom